Quarterly report pursuant to Section 13 or 15(d)

Condensed Statements of Operations

v3.21.2
Condensed Statements of Operations - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Operating expenses:        
Research and development $ 2,961,122 $ 108,086 $ 7,877,281 $ 161,944
General and administrative expenses 1,150,369 2,554,724 3,576,101 3,421,798
Total operating expenses 4,111,491 2,662,810 11,453,382 3,583,742
Loss from operations (4,111,491) (2,662,810) (11,453,382) (3,583,742)
Other income (expense):        
Interest income (expense), net 1,509 (104,440) 4,405 (304,646)
Other income   43,221   43,221
Total other income (expense) 1,509 (61,219) 4,405 (261,425)
Loss before income taxes (4,109,982) (2,724,029) (11,448,977) (3,845,167)
Net loss $ (4,109,982) $ (2,724,029) $ (11,448,977) $ (3,845,167)
Basic and diluted net loss per share $ (0.49) $ (0.56) $ (1.37) $ (0.80)
Weighted average number of shares outstanding - basic and diluted 8,330,390 4,832,494 8,328,946 4,832,494